NCT06511934 Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01)
| NCT ID | NCT06511934 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Leigh R. Hochberg, MD, PhD. |
| Condition | Brainstem Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 6 participants |
| Start Date | 2024-07-22 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 6 participants in total. It began in 2024-07-22 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
People with brainstem stroke, advanced amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease), or other disorders can become unable to move or speak despite being awake and alert. In this project, the investigators seek to further translate knowledge about interpreting brain signals related to movement, and to further develop an intracortical brain-computer interface (iBCI) that could restore rapid and intuitive use of communication apps on tablet computers by people with paralysis.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders * Complete or incomplete tetraplegia (quadriplegia) * Must live within a three-hour drive of the Study site * Prior enrollment in BrainGate2 clinical trial (NCT00912041) Exclusion Criteria: * Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses * Chronic oral or intravenous steroids or immunosuppressive therapy * Other serious disease or disorder that could seriously affect ability to participate in the study (There are additional exclusion criteria)
Contact & Investigator
Leigh R Hochberg, MD, Ph.D.
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT06511934 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Brainstem Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06511934 currently recruiting?
Yes, NCT06511934 is actively recruiting participants. Contact the research team at lhochberg@mgh.harvard.edu for enrollment information.
Where is the NCT06511934 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06511934 clinical trial?
NCT06511934 is sponsored by Leigh R. Hochberg, MD, PhD.. The principal investigator is Leigh R Hochberg, MD, Ph.D. at Massachusetts General Hospital. The trial plans to enroll 6 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.